Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 59 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Iris Neoplasms Clear all
Completed Phase 2 Interventional

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

NCT00085189
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma, Iris Melanoma, Metastatic Intraocular Melanoma, Mucosal Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage IIC Melanoma, Stage IIIA Intraocular Melanoma, Stage IIIA Melanoma, Stage IIIB Intraocular Melanoma, Stage IIIB Melanoma, Stage IIIC Intraocular Melanoma, Stage IIIC Melanoma, Stage IV Intraocular Melanoma, Stage IV Melanoma
Interventions
gp100 antigen, tyrosinase peptide, recombinant MAGE-3.1 antigen, multi-epitope melanoma peptide vaccine, incomplete Freund's adjuvant, Montanide ISA 51 VG, agatolimod sodium, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
University of Southern California
Other
Eligibility
16 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Jul 21, 2026, 11:00 AM EDT
Completed Phase 1 Interventional Results available

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

NCT01770353
View directory record Official record
Conditions
Solid Tumors, ER/PR Positive Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer With Active Brain Metastasis
Interventions
Ferumoxytol, MM-398
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
7
States / cities
Scottsdale, Arizona • San Francisco, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Jul 21, 2026, 11:00 AM EDT
Terminated Early Phase 1 Interventional

Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases

NCT01730157
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma, Iris Melanoma, Liver Metastases, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Stage IV Intraocular Melanoma
Interventions
ipilimumab, yttrium Y 90 glass microspheres, laboratory biomarker analysis
Biological · Radiation · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Jul 21, 2026, 11:00 AM EDT
Completed No phase listed Observational

A Prospective Post-Market Study to Evaluate the Clinical Utility of IRIS, a Three-dimensional (3-D) Anatomical Modeling Software for Pre-operative Surgical Planning and Intra-operative Navigation for Nephrectomy

NCT04329767
View directory record Official record
Conditions
Kidney Cancer
Interventions
IRIS 1.0
Device
Lead sponsor
Intuitive Surgical
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Edison, New Jersey • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Jul 21, 2026, 11:00 AM EDT
Completed Phase 2 Interventional Results available

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

NCT00084656
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
ipilimumab, Tyrosinase/gp100/MART-1 Peptides
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 120 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Jul 21, 2026, 11:00 AM EDT
Completed Phase 2 Interventional

Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer

NCT00096083
View directory record Official record
Conditions
Cancer
Interventions
isolated perfusion, melphalan
Drug
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
16 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced Jul 21, 2026, 11:00 AM EDT
Completed Phase 2 Interventional

Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma

NCT00085306
View directory record Official record
Conditions
Stage IV Melanoma, Recurrent Melanoma
Interventions
recombinant interferon beta
Biological
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Jul 21, 2026, 11:00 AM EDT
Completed Phase 1 Interventional

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00020579
View directory record Official record
Conditions
Cancer
Interventions
entinostat
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Jul 21, 2026, 11:00 AM EDT
Withdrawn No phase listed Observational

Validation of a Molecular Prognostic Test for Eye Melanoma

NCT00406120
View directory record Official record
Conditions
Uveal Neoplasms, Choroid Neoplasms, Iris Neoplasms
Interventions
Fine needle aspiration biopsy
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Jul 21, 2026, 11:00 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

NCT00032045
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
gp100 antigen, incomplete Freund's adjuvant, ipilimumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Jul 21, 2026, 11:00 AM EDT
Not listed Phase 1 Interventional

Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer

NCT03703063
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Gemcitabine, nab paclitaxel, Onivyde, Leucovorin, 5-fu
Drug
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Jul 21, 2026, 11:00 AM EDT
Completed Phase 2 Interventional Results available

Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye

NCT01413191
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Metastatic Intraocular Melanoma, Recurrent Intraocular Melanoma, Stage IV Intraocular Melanoma
Interventions
Cixutumumab, Laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
17 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Jul 21, 2026, 11:00 AM EDT
Completed Not applicable Interventional Results available

Volumetric Laser Endomicroscopy With Intelligent Real-time Image Segmentation (IRIS)

NCT03814824
View directory record Official record
Conditions
Barrett's Esophagus Without Dysplasia, Barrett's Esophagus With Dysplasia, Barrett's Esophagus With Low Grade Dysplasia, Barrett's Esophagus With High Grade Dysplasia, Barrett's Esophagus With Dysplasia, Unspecified
Interventions
IRIS (Intelligent real-time image segmentation), VLE (Volumetric laser endomicroscopy)
Diagnostic Test
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Scottsdale, Arizona • Rochester, Minnesota • Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Jul 21, 2026, 11:00 AM EDT
Completed Phase 3 Interventional

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

NCT00324727
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin), Metastatic Cancer
Interventions
melphalan, regional chemotherapy, systemic chemotherapy, hepatic artery embolization
Drug · Procedure
Lead sponsor
Delcath Systems Inc.
Industry
Eligibility
18 Years to 120 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
12
States / cities
Santa Monica, California • Englewood, Colorado • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2021 · Synced Jul 21, 2026, 11:00 AM EDT
Completed Phase 1 Interventional

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

NCT05628883
View directory record Official record
Conditions
Metastatic Melanoma, Unresectable Melanoma, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, Ocular Melanoma, Uveal Melanoma, Iris Melanoma, Conjunctival Melanoma, Non-Cutaneous Melanoma
Interventions
TBio-4101, Cyclophosphamide, Fludarabine, Interleukin-2
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jul 21, 2026, 11:00 AM EDT
Completed Phase 1Phase 2 Interventional

Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00058279
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
aldesleukin, ipilimumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Jul 21, 2026, 11:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Use of Traditional Curved Iris Scissors or the Wuennenberg Modified Curved Iris Scissors for Skin Surgery

NCT04413383
View directory record Official record
Conditions
Skin Cancer
Interventions
Traditional Curved Iris Scissors, Wuennenberg Modified Curved Iris Scissors, Comparative Experience of Traditional and Wuennenberg Modified Curved Iris Scissors
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Jul 21, 2026, 11:00 AM EDT
Completed Phase 2 Interventional Results available

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery

NCT00738361
View directory record Official record
Conditions
Intraocular Melanoma
Interventions
nab-paclitaxel
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 11, 2016 · Synced Jul 21, 2026, 11:00 AM EDT
Recruiting Phase 2 Interventional

Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer

NCT05806931
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
TAS-102, oxaliplatin, irinotecan with bevacizumab
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Elizabeth, New Jersey • Jersey City, New Jersey • Lakewood, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jul 21, 2026, 11:00 AM EDT
Terminated Not applicable Interventional Results available

Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases

NCT02336763
View directory record Official record
Conditions
Iris Melanoma, Medium/Large Size Posterior Uveal Melanoma, Stage IIA Uveal Melanoma, Stage IIB Uveal Melanoma, Stage IIIA Uveal Melanoma, Stage IIIB Uveal Melanoma, Stage IIIC Uveal Melanoma
Interventions
External Beam Radiation Therapy, Laboratory Biomarker Analysis
Radiation · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Jul 21, 2026, 11:00 AM EDT
Completed Phase 1 Interventional

Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery

NCT00025181
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, ipilimumab, tyrosinase peptide, adjuvant therapy
Biological · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Jul 21, 2026, 11:00 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Characterization of WAGR Syndrome and Other Chromosome 11 Gene Deletions

NCT00758108
View directory record Official record
Conditions
WAGR Syndrome, Wilm's Tumor, Aniridia, Urogenital Abnormalities, Mental Retardation
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
2 Years to 99 Years
Enrollment
197 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Jul 21, 2026, 11:00 AM EDT
Completed Phase 2 Interventional Results available

Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma

NCT02551991
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
nal-IRI, 5 fluorouracil, Leucovorin, Oxaliplatin
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
29
States / cities
Mobile, Alabama • Avondale, Arizona • Phoenix, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Jul 21, 2026, 11:00 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

NCT00471471
View directory record Official record
Conditions
Intraocular Melanoma, Malignant Conjunctival Neoplasm, Melanoma (Skin)
Interventions
Peptide vaccine, GM-CSF, PF3512676
Biological
Lead sponsor
Ahmad Tarhini
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Jul 21, 2026, 11:00 AM EDT